• Explore /
  • Videos & Slides
  • / Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Abstract Video & Slides

Presenter

null

Jerome Fayette, MD, PhD

Centre Leon Bérard, Medical Oncology

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2023 ASCO Annual Meeting

Session Type

Oral Abstract Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT0372967

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6003)

DOI

10.1200/JCO.2023.41.16_suppl.6003

Abstract #

6003

Abstract Disclosures

Similar Videos & Slides

Speaker: Lara Iglesias, MD

Speaker: Tiandong Kong

Speaker: Jared Cohen, MD

Speaker: Jianqing Zhu, MD